Developer docs
API playgroundTry for free, no card

Search company profiles

NimBio

Full company profile

uuid0003weo

Namestring
NimBio
Legal namestring
Nimbio
Websiteurl
nimbio.ai
Company typeenum
Private
Founded yearint
2023
Descriptiontext

NimBio is an early-stage digital health company, founded in 2023 and headquartered in Amsterdam, that builds an AI-driven wearable inflammation monitoring platform aimed at Inflammatory Bowel Disease patients. Its core product, the Inflammometer, uses photoplethysmography (PPG) waveform analysis captured through everyday wearables to provide continuous, non-invasive tracking of inflammatory status and to deliver early warning of impending IBD flares before symptoms manifest. Companion smartwatch and tablet interfaces surface real-time inflammation status to patients, while a backend platform attributes flare causes such as treatment failure or poor adherence and generates therapeutic recommendations.

Underlying capabilities combine passive bio-sensing with predictive AI spanning anomaly detection, flare forecasting, and treatment optimization, validated through a completed clinical proof-of-concept and ongoing studies across three medical centers. The company has presented its PPG-based approach at the ECCO'24 Congress and as an oral lecture at DDW2024, and is supported by the eHealth Ventures portfolio with disclosed investment from European VC Venturing Holding BV.

NimBio operates a B2B2C model serving four segments: IBD patients (consumers of the wearable and app), hospitals and physicians (remote patient monitoring), pharmaceutical companies (treatment optimization and real-world evidence), and payers or insurers (hospitalization reduction). Pricing is not publicly disclosed; the go-to-market is enterprise-led, anchored by an April 2025 memorandum of understanding with Takeda Belgium, KU Leuven, and EIT Health to launch clinical pilots, with marketing concentrated in healthcare conferences (HLTH, ECCO, DDW) and category-defining award platforms such as the EIT Health Catapult. The company is private, pre-revenue in disclosed terms, and currently active in the Netherlands and Belgium, with US-facing activity beginning in 2025.

Short descriptiontext

NimBio is an early-stage Amsterdam-based digital health company building the Inflammometer, an AI-driven wearable platform that uses PPG waveform analysis to continuously monitor inflammation and predict IBD flares for patients, clinicians, pharmaceutical companies, and payers across Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAmsterdam, Netherlands
HQ citystring
Amsterdam
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wearable inflammation monitoring, IBD flare detection, digital biomarker tracking, remote patient monitoring, AI predictive analytics
Industry2 codes
PRIMARYHLAKAEAD
Inflammatory Bowel Disease (IBD) Care
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Digital Health / Remote Patient Monitoring
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Healthcare Monitoring Platform
TypeSubscription Recurring
Description

B2B2C model providing inflammation monitoring services to healthcare providers, pharma companies, and payers. Revenue likely derives from platform licensing, per-patient monitoring fees, and outcomes-based contracts with payers.

nimbio.ai
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Inflammometer
Description

A wearable-powered, AI-driven inflammation monitor that provides continuous tracking of inflammation levels through everyday wearables, detecting early warning signs of IBD flares before symptoms appear.

nimbio.ai
Core offering1 text field

NimBio develops and sells the Inflammometer, an AI-driven, wearable-powered inflammation monitoring platform that uses passive bio-sensing and photoplethysmography (PPG) waveform analysis to continuously track inflammation biomarkers in patients with Inflammatory Bowel Disease (IBD). The platform identifies flare-up causes (treatment failure, poor adherence) and offers real-time therapeutic recommendations for healthcare providers, pharmaceutical companies, and payers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Successfully completed clinical POC study with ongoing validation at three medical centers
+1 more record
Product overview1 text field

NimBio offers a unified remote care solution for Inflammatory Bowel Disease (IBD) patients consisting of the Inflammometer (wearable-powered AI inflammation monitor) and the NimBio Platform. The Inflammometer is a wearable device that uses passive bio-sensing to continuously track inflammation biomarkers and provide real-time inflammation status, while the NimBio Platform analyzes this data to identify flare-up causes and deliver personalized therapeutic recommendations. The solution includes smartwatch and tablet UI components for patient interaction. The company is conducting clinical validation studies across multiple medical centers.

Product and service2 records
1Inflammometer
CategoryDigital Health Platform
Description

A wearable-powered, AI-driven inflammation monitor that continuously tracks inflammation levels through everyday wearables using passive bio-sensing, providing real-time inflammation status and detecting early warning signs of IBD flares before symptoms appear. Designed for IBD patients, healthcare providers, and pharmaceutical partners.

2NimBio Platform
CategoryRemote Care Software Platform
Description

A remote care platform that integrates wearable bio-sensing data to identify flare-up causes (such as treatment failure or poor medical adherence) and offers therapeutic recommendations in real time. Provides personalized early flare detection for healthcare providers, pharma companies, and payers managing IBD patient populations.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-30
Description

EIT Health Open Innovation programme selected NimBio as finalist and supported the partnership with Takeda Belgium and KU Leuven. EIT Health brought together healthcare providers and industry experts to identify urgent unmet needs, facilitating NimBio's clinical pilot program. The organization continues to provide mentorship and platform access through the Catapult program.

2Takeda Belgium
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-30
Description

Takeda Belgium partnered with NimBio following the EIT Health IBD Challenge. They highlighted the shared challenge of detecting IBD flares earlier and enabling more personalized, proactive care. Takeda will explore integration with their 'For You With You' digital platform. A Memorandum of Understanding (MoU) was signed to launch a clinical pilot testing the Inflammometer.

nimbio.ai
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-30
Description

KU Leuven is a key academic partner in the clinical pilot program, providing real-world hospital setting for testing the Inflammometer with actual patients. As a leading European research university with strong medical faculty, KU Leuven brings clinical expertise and patient access for validation studies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Digital health platform for remote patient monitoring and decentralized clinical trials, used by major pharma and health systems. Comparable in RPM and predictive analytics capabilities, broader in therapeutic coverage.

TypeDirect peer
Description

Virtual-first gastroenterology care platform combining digital tools with clinician support for IBD/IBS patients, sold to payers and employers. Comparable in disease focus, multi-stakeholder value proposition, and B2B2C economics.

TypeBroad incumbent
Description

Pioneer in digital therapeutics and chronic disease management platforms (with FDA-cleared products). Comparable as a regulated, B2B-focused digital health platform addressing chronic conditions.

TypeDirect peer
Description

Digital GI health platform offering condition management, nutrition, and remote monitoring for IBD and IBS patients via B2B payer/employer channels. Highly comparable in disease focus, target population, and enterprise GTM motion.

5Biofourmis
TypeBroad incumbent
Description

Established remote patient monitoring and predictive analytics platform spanning multiple therapeutic areas using wearable biosensors and AI. Comparable technology stack (wearables + AI + RPM) but operates broadly rather than IBD-specific.

TypeDirect peer
Description

Developer of prescription digital therapeutics for GI conditions including IBS, with regulatory-cleared software products addressing gut-brain interaction. Comparable as a digital therapeutic targeting the same patient population.

TypeEmerging player
Description

Digital health platform for IBD and IBS combining behavioral, dietary, and clinical support. Comparable as an emerging GI-focused digital health company with similar B2B2C ambitions.

TypeDirect peer
Description

Digital health platform specifically focused on IBD and other immune-mediated conditions, providing resilience-based care and remote monitoring. Closest direct comparable to NimBio given overlapping IBD focus and B2B2C enterprise model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NimBio

Digital Health / Remote Patient Monitoringnimbio.ai

NimBio is an early-stage Amsterdam-based digital health company building the Inflammometer, an AI-driven wearable platform that uses PPG waveform analysis to continuously monitor inflammation and predict IBD flares for patients, clinicians, pharmaceutical companies, and payers across Europe.

What NimBio does

NimBio is an early-stage digital health company, founded in 2023 and headquartered in Amsterdam, that builds an AI-driven wearable inflammation monitoring platform aimed at Inflammatory Bowel Disease patients. Its core product, the Inflammometer, uses photoplethysmography (PPG) waveform analysis captured through everyday wearables to provide continuous, non-invasive tracking of inflammatory status and to deliver early warning of impending IBD flares before symptoms manifest. Companion smartwatch and tablet interfaces surface real-time inflammation status to patients, while a backend platform attributes flare causes such as treatment failure or poor adherence and generates therapeutic recommendations.

Underlying capabilities combine passive bio-sensing with predictive AI spanning anomaly detection, flare forecasting, and treatment optimization, validated through a completed clinical proof-of-concept and ongoing studies across three medical centers. The company has presented its PPG-based approach at the ECCO'24 Congress and as an oral lecture at DDW2024, and is supported by the eHealth Ventures portfolio with disclosed investment from European VC Venturing Holding BV.

NimBio operates a B2B2C model serving four segments: IBD patients (consumers of the wearable and app), hospitals and physicians (remote patient monitoring), pharmaceutical companies (treatment optimization and real-world evidence), and payers or insurers (hospitalization reduction). Pricing is not publicly disclosed; the go-to-market is enterprise-led, anchored by an April 2025 memorandum of understanding with Takeda Belgium, KU Leuven, and EIT Health to launch clinical pilots, with marketing concentrated in healthcare conferences (HLTH, ECCO, DDW) and category-defining award platforms such as the EIT Health Catapult. The company is private, pre-revenue in disclosed terms, and currently active in the Netherlands and Belgium, with US-facing activity beginning in 2025.

NimBio firmographics

Firmographics
Name
NimBio
Legal name
Nimbio
Website
https://nimbio.ai
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
NimBio is an early-stage Amsterdam-based digital health company building the Inflammometer, an AI-driven wearable platform that uses PPG waveform analysis to continuously monitor inflammation and predict IBD flares for patients, clinicians, pharmaceutical companies, and payers across Europe.
Ownership category
akta.pro rank

NimBio industry classification

Industry
Product category
Digital Health / Remote Patient Monitoring
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAKAEAD
Inflammatory Bowel Disease (IBD) Care
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Keywords

  • Wearable inflammation monitoring
  • IBD flare detection
  • Digital biomarker tracking
  • Remote patient monitoring
  • AI predictive analytics

Where NimBio is headquartered

Location

Headquarters

HQ city
Amsterdam
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

NimBio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Healthcare Monitoring Platform: B2B2C model providing inflammation monitoring services to healthcare providers, pharma companies, and payers. Revenue likely derives from platform licensing, per-patient monitoring fees, and outcomes-based contracts with payers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

NimBio product offering

Product offering

Core offering

NimBio develops and sells the Inflammometer, an AI-driven, wearable-powered inflammation monitoring platform that uses passive bio-sensing and photoplethysmography (PPG) waveform analysis to continuously track inflammation biomarkers in patients with Inflammatory Bowel Disease (IBD). The platform identifies flare-up causes (treatment failure, poor adherence) and offers real-time therapeutic recommendations for healthcare providers, pharmaceutical companies, and payers.

Product overview

NimBio offers a unified remote care solution for Inflammatory Bowel Disease (IBD) patients consisting of the Inflammometer (wearable-powered AI inflammation monitor) and the NimBio Platform. The Inflammometer is a wearable device that uses passive bio-sensing to continuously track inflammation biomarkers and provide real-time inflammation status, while the NimBio Platform analyzes this data to identify flare-up causes and deliver personalized therapeutic recommendations. The solution includes smartwatch and tablet UI components for patient interaction. The company is conducting clinical validation studies across multiple medical centers.

Differentiator

Problem solved

Functional benefit

Brands

  • Inflammometer: A wearable-powered, AI-driven inflammation monitor that provides continuous tracking of inflammation levels through everyday wearables, detecting early warning signs of IBD flares before symptoms appear.

Products and services

  • Inflammometer A wearable-powered, AI-driven inflammation monitor that continuously tracks inflammation levels through everyday wearables using passive bio-sensing, providing real-time inflammation status and detecting early warning signs of IBD flares before symptoms appear. Designed for IBD patients, healthcare providers, and pharmaceutical partners.
  • NimBio Platform A remote care platform that integrates wearable bio-sensing data to identify flare-up causes (such as treatment failure or poor medical adherence) and offers therapeutic recommendations in real time. Provides personalized early flare detection for healthcare providers, pharma companies, and payers managing IBD patient populations.

Quantifiable outcome

  • Successfully completed clinical POC study with ongoing validation at three medical centers
  • +1 more outcomes

Companies that use NimBio

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

NimBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

NimBio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • EIT HealthcoreStrategic or Co-development Partner · 30 April 2025EIT Health Open Innovation programme selected NimBio as finalist and supported the partnership with Takeda Belgium and KU Leuven. EIT Health brought together healthcare providers and industry experts to identify urgent unmet needs, facilitating NimBio's clinical pilot program. The organization continues to provide mentorship and platform access through the Catapult program.
  • Takeda BelgiumcoreStrategic or Co-development Partner · 30 April 2025Takeda Belgium partnered with NimBio following the EIT Health IBD Challenge. They highlighted the shared challenge of detecting IBD flares earlier and enabling more personalized, proactive care. Takeda will explore integration with their 'For You With You' digital platform. A Memorandum of Understanding (MoU) was signed to launch a clinical pilot testing the Inflammometer.
  • KU LeuvencoreStrategic or Co-development Partner · 30 April 2025KU Leuven is a key academic partner in the clinical pilot program, providing real-world hospital setting for testing the Inflammometer with actual patients. As a leading European research university with strong medical faculty, KU Leuven brings clinical expertise and patient access for validation studies.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

NimBio competitors and assessment

Company assessment

Broad incumbents

  • Huma: Digital health platform for remote patient monitoring and decentralized clinical trials, used by major pharma and health systems. Comparable in RPM and predictive analytics capabilities, broader in therapeutic coverage.
  • WellDoc: Pioneer in digital therapeutics and chronic disease management platforms (with FDA-cleared products). Comparable as a regulated, B2B-focused digital health platform addressing chronic conditions.
  • Biofourmis: Established remote patient monitoring and predictive analytics platform spanning multiple therapeutic areas using wearable biosensors and AI. Comparable technology stack (wearables + AI + RPM) but operates broadly rather than IBD-specific.

Direct peers

  • Oshi Health: Virtual-first gastroenterology care platform combining digital tools with clinician support for IBD/IBS patients, sold to payers and employers. Comparable in disease focus, multi-stakeholder value proposition, and B2B2C economics.
  • Vivante Health: Digital GI health platform offering condition management, nutrition, and remote monitoring for IBD and IBS patients via B2B payer/employer channels. Highly comparable in disease focus, target population, and enterprise GTM motion.
  • Mahana Therapeutics: Developer of prescription digital therapeutics for GI conditions including IBS, with regulatory-cleared software products addressing gut-brain interaction. Comparable as a digital therapeutic targeting the same patient population.
  • Trellus Health: Digital health platform specifically focused on IBD and other immune-mediated conditions, providing resilience-based care and remote monitoring. Closest direct comparable to NimBio given overlapping IBD focus and B2B2C enterprise model.

Emerging players

  • Ayble Health: Digital health platform for IBD and IBS combining behavioral, dietary, and clinical support. Comparable as an emerging GI-focused digital health company with similar B2B2C ambitions.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

NimBio social profiles

Digital presence

NimBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NimBio leadership team

Management profile

Number of profiles

Profiles2 records

NimBio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NimBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NimBio

What does NimBio do?

NimBio develops and sells the Inflammometer, an AI-driven, wearable-powered inflammation monitoring platform that uses passive bio-sensing and photoplethysmography (PPG) waveform analysis to continuously track inflammation biomarkers in patients with Inflammatory Bowel Disease (IBD). The platform identifies flare-up causes (treatment failure, poor adherence) and offers real-time therapeutic recommendations for healthcare providers, pharmaceutical companies, and payers.

Is NimBio a public or private company?

NimBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was NimBio founded?

NimBio was founded in 2023. It employs 1 to 10 people.

Where is NimBio based?

NimBio is headquartered in Amsterdam, Netherlands, in the Europe region.

How does NimBio make money?

One revenue line is on record: healthcare Monitoring Platform.

Who are NimBio's main competitors?

Broad incumbents on record are Huma, WellDoc and Biofourmis. Direct peers are Oshi Health, Vivante Health, Mahana Therapeutics and Trellus Health. Ayble Health is listed as an emerging player.

Does NimBio have an API?

No public API is recorded for NimBio.

What industry is NimBio in?

NimBio's product category is Digital Health / Remote Patient Monitoring. Its primary akta.pro industry code is HLAKAEAD, Inflammatory Bowel Disease (IBD) Care, with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals